Enovis will host a conference call on August 6, 2026, to discuss Q2 financial results, accessible via its website.
Quiver AI Summary
Enovis™ Corporation, a medical technology company, announced it will hold an investor conference call and live webcast to discuss its second quarter 2026 financial results on August 6, 2026, at 8:30 a.m. Eastern Time. An earnings press release will be issued earlier that same day. Interested parties can access the live webcast on Enovis' website, and those wishing to participate in the call can do so by dialing specific numbers provided for U.S. and international callers, using a designated conference ID. A replay of the call will also be available on the website later. Enovis aims to improve patient outcomes through innovative medical solutions and regularly communicates important information to investors via various platforms, encouraging stakeholders to stay informed through its Investor Relations website.
Potential Positives
- Enovis Corporation is set to discuss its second quarter 2026 financial results, indicating transparency and engagement with investors.
- The company is leveraging technology by hosting a live webcast for the investor conference call, which can enhance accessibility for a wider audience.
- The scheduled earnings press release indicates that Enovis is committed to timely communication of its financial performance to the market.
FAQ
When is the Enovis investor conference call scheduled?
The Enovis investor conference call is scheduled for Thursday, August 6th, 2026, at 8:30 a.m. Eastern Time.
How can I access the Enovis conference call and webcast?
Investors can access the live webcast via a link on the Enovis website at www.enovis.com.
What is the Conference ID for the Enovis conference call?
The Conference ID for the Enovis conference call is 6602335.
Will there be a replay available for the Enovis conference call?
Yes, a link to a replay of the call will be available on the Enovis website later that day.
What does Enovis Corporation specialize in?
Enovis Corporation specializes in developing innovative medical technology solutions that enhance patient outcomes and restore motion for life.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
EARLY ACCESS
Receive ENOV Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$ENOV Insider Trading Activity
$ENOV insiders have traded $ENOV stock on the open market 13 times in the past 6 months. Of those trades, 13 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ENOV stock by insiders over the last 6 months:
- OLIVER ENGERT (Chief Administrative Officer) has made 13 purchases buying 10,200 shares for an estimated $238,003 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ENOV Revenue
$ENOV had revenues of $589.2M in Q1 2026. This is an increase of 5.43% from the same period in the prior year.
You can track ENOV financials on Quiver Quantitative's ENOV stock page.
You can access data on ENOV stock through the Quiver Quantitative API.
$ENOV Hedge Fund Activity
We have seen 120 institutional investors add shares of $ENOV stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DORSEY ASSET MANAGEMENT, LLC removed 2,279,200 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $51,851,800
- BLACKROCK, INC. added 1,029,845 shares (+11.6%) to their portfolio in Q1 2026, for an estimated $23,428,973
- WALLEYE CAPITAL LLC removed 1,015,356 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $23,099,349
- GOLDMAN SACHS GROUP INC added 720,006 shares (+84.9%) to their portfolio in Q1 2026, for an estimated $16,380,136
- FMR LLC removed 567,682 shares (-29.4%) from their portfolio in Q1 2026, for an estimated $12,914,765
- CITADEL ADVISORS LLC added 546,383 shares (+232.1%) to their portfolio in Q1 2026, for an estimated $12,430,213
- EXODUSPOINT CAPITAL MANAGEMENT, LP removed 508,971 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $11,579,090
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ENOV Analyst Ratings
Wall Street analysts have issued reports on $ENOV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 04/17/2026
- Needham issued a "Buy" rating on 02/26/2026
To track analyst ratings and price targets for $ENOV, check out Quiver Quantitative's $ENOV forecast page.
$ENOV Price Targets
Multiple analysts have issued price targets for $ENOV recently. We have seen 5 analysts offer price targets for $ENOV in the last 6 months, with a median target of $39.0.
Here are some recent targets:
- Vik Chopra from BMO Capital set a target price of $29.0 on 07/09/2026
- Vijay Kumar from Evercore ISI Group set a target price of $32.0 on 07/06/2026
- Ryan Zimmerman from BTIG set a target price of $39.0 on 05/22/2026
- Larry Biegelsen from Wells Fargo set a target price of $40.0 on 05/08/2026
- Mike Matson from Needham set a target price of $52.0 on 02/26/2026
Full Release
Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2026 financial results on Thursday, August 6th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at
www.enovis.com
.
Conference Call/Webcast Information
Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9871 (U.S. callers) and (646) 307-1963 (International callers) and use Conference ID: 6602335. A link to a replay of the call will also be available on the Enovis website later that day.
About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at
www.enovis.com
.
Availability of Information on the Enovis Website
Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
investorrelations@enovis.com
Read full article here »
View the Zacks #1 Rank List
Enovis Corporation to Host Second Quarter 2026 Investor Conference Call and Webcast on August 6
Enovis will host a conference call on August 6, 2026, to discuss Q2 financial results, accessible via its website.
Quiver AI Summary
Enovis™ Corporation, a medical technology company, announced it will hold an investor conference call and live webcast to discuss its second quarter 2026 financial results on August 6, 2026, at 8:30 a.m. Eastern Time. An earnings press release will be issued earlier that same day. Interested parties can access the live webcast on Enovis' website, and those wishing to participate in the call can do so by dialing specific numbers provided for U.S. and international callers, using a designated conference ID. A replay of the call will also be available on the website later. Enovis aims to improve patient outcomes through innovative medical solutions and regularly communicates important information to investors via various platforms, encouraging stakeholders to stay informed through its Investor Relations website.
Potential Positives
Potential Negatives
FAQ
When is the Enovis investor conference call scheduled?
The Enovis investor conference call is scheduled for Thursday, August 6th, 2026, at 8:30 a.m. Eastern Time.
How can I access the Enovis conference call and webcast?
Investors can access the live webcast via a link on the Enovis website at www.enovis.com.
What is the Conference ID for the Enovis conference call?
The Conference ID for the Enovis conference call is 6602335.
Will there be a replay available for the Enovis conference call?
Yes, a link to a replay of the call will be available on the Enovis website later that day.
What does Enovis Corporation specialize in?
Enovis Corporation specializes in developing innovative medical technology solutions that enhance patient outcomes and restore motion for life.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ENOV Insider Trading Activity
$ENOV insiders have traded $ENOV stock on the open market 13 times in the past 6 months. Of those trades, 13 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ENOV stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ENOV Revenue
$ENOV had revenues of $589.2M in Q1 2026. This is an increase of 5.43% from the same period in the prior year.
You can track ENOV financials on Quiver Quantitative's ENOV stock page.
You can access data on ENOV stock through the Quiver Quantitative API.
$ENOV Hedge Fund Activity
We have seen 120 institutional investors add shares of $ENOV stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ENOV Analyst Ratings
Wall Street analysts have issued reports on $ENOV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $ENOV, check out Quiver Quantitative's $ENOV forecast page.
$ENOV Price Targets
Multiple analysts have issued price targets for $ENOV recently. We have seen 5 analysts offer price targets for $ENOV in the last 6 months, with a median target of $39.0.
Here are some recent targets:
Full Release
Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2026 financial results on Thursday, August 6th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com .
Conference Call/Webcast Information
Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9871 (U.S. callers) and (646) 307-1963 (International callers) and use Conference ID: 6602335. A link to a replay of the call will also be available on the Enovis website later that day.
About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com .
Availability of Information on the Enovis Website
Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
investorrelations@enovis.com
Read full article here »